Trial Profile
A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Eragidomide (Primary) ; Dexamethasone
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 27 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2022 Planned End Date changed from 26 Sep 2025 to 13 Jul 2025.
- 20 Sep 2022 Planned primary completion date changed from 25 Sep 2024 to 12 Jul 2024.